Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The stock was sold at an average price of $11.05, for a total transaction of $22,100.00. Following the sale, the president now owns 2,940,467 shares of the company’s stock, valued at approximately $32,492,160.35. This represents a 0.07 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Gyre Therapeutics Stock Down 0.4 %

Gyre Therapeutics stock traded down $0.04 during trading hours on Thursday, hitting $10.66. The company had a trading volume of 112,081 shares, compared to its average volume of 74,347. The firm has a 50-day moving average of $12.93 and a 200 day moving average of $12.59. Gyre Therapeutics, Inc. has a one year low of $8.26 and a one year high of $30.40.

Institutional Trading of Gyre Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. FMR LLC acquired a new position in Gyre Therapeutics in the 3rd quarter valued at $47,000. Barclays PLC boosted its position in shares of Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the period. Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics in the second quarter valued at about $123,000. Renaissance Technologies LLC acquired a new stake in Gyre Therapeutics in the 2nd quarter worth about $166,000. Finally, Bank of New York Mellon Corp bought a new stake in Gyre Therapeutics in the 2nd quarter valued at about $218,000. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.